Company

Asclepiumm Taiwan Co., Ltd. was established in 2011 and is a pioneering pharmaceutical development company focused on addressing unmet medical needs in the market. The company specializes in the research and development of innovative first-in-class drugs utilizing the ASC fusion protein platform and unique peptide drug development. In 2016, Asclepiumm established three major research axes: peptides, antibodies, and fusion proteins.

 

As of 2023, the company has developed two series of peptide drugs, an antibody platform, and a fusion protein drug platform, all of which have been granted patents in the United States, China, and Japan. These research achievements will be further developed through collaborations with professional Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) in the subsequent phases of drug development.

 

The products under development are characterized by their novelty, addressing urgent medical needs, and the potential to become blockbuster drugs with annual sales exceeding 1 billion USD. There are opportunities for early-stage licensing and collaboration with international pharmaceutical giants, which can accelerate and enhance the success of new drug development and contribute to the expansion of future markets.